Gerresheimer is reportedly looking at further acquisitions, following its $725 million buy of U.S. plastic vial maker Centor.

The company’s Chief Financial Officer, Rainer Beaujean, said in an interview with the Boersen-Zeitung that "acquisitions like those we did in the past years in emerging markets with a price of 50 to 70 million euros [$55 to $77 million] are always possible.”

Mr. Beaujean named India and China as the most important markets for Gerresheimer in the future.

He said that the company’s management sees these markets as having potential for products such as insulin pens and inhalers in the long term, but that these must be more simple and cheaper than those in Western Europe.